BORTIB

Advanced Proteasome Inhibitor for Blood Cancer Treatment

BORTIB is a prescription-based anticancer medicine containing Bortezomib, a proteasome inhibitor indicated for the treatment of Multiple Myeloma (MM) and Mantle Cell Lymphoma (MCL). It is widely used in modern hematology and oncology either as a single-agent therapy or in combination with other anticancer medicines to improve treatment outcomes.

BORTIB works by selectively inhibiting proteasomes—protein complexes responsible for breaking down damaged or unwanted proteins inside cells. Cancer cells rely heavily on proteasomes for survival. By blocking this process, BORTIB causes the accumulation of abnormal proteins, triggering cancer cell death while slowing disease progression.

Administered by trained healthcare professionals, BORTIB plays a vital role in comprehensive treatment plans for patients with blood cancers.

Key Benefits of BORTIB

• Contains Bortezomib, a clinically proven proteasome inhibitor
• Effective treatment for Multiple Myeloma
• Used in the management of Mantle Cell Lymphoma (MCL)
• Helps destroy cancer cells by inhibiting proteasome activity
• Slows disease progression and supports long-term treatment
• Can be used alone or in combination with other chemotherapy medicines
• Administered under specialist hematology and oncology supervision
• Trusted targeted therapy for blood cancers

Uses of BORTIB

BORTIB is commonly prescribed for the treatment of:

• Multiple Myeloma (MM)
• Mantle Cell Lymphoma (MCL)
• Relapsed or refractory Multiple Myeloma
• Relapsed or refractory Mantle Cell Lymphoma
• Other approved hematological malignancies as recommended by a healthcare specialist

Why Choose BORTIB?

BORTIB is a globally recognized targeted therapy that has significantly improved the treatment of Multiple Myeloma and Mantle Cell Lymphoma. Its proven clinical effectiveness, targeted mechanism of action, and ability to be combined with other anticancer medicines make it an important part of modern blood cancer treatment protocols.

Important Safety Information

• Prescription-only anticancer medicine.
• Must be administered by trained healthcare professionals.
• Regular monitoring of blood counts, liver function, kidney function, and nerve health is recommended during treatment.
• Inform your doctor if you have liver disease, kidney disease, diabetes, heart disease, or peripheral neuropathy.
• Do not self-administer or discontinue treatment without medical advice.
• Keep out of reach of children.